Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03367702
Recruitment Status : Recruiting
First Posted : December 11, 2017
Last Update Posted : June 20, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NRG Oncology

Brief Summary:
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Condition or disease Intervention/treatment Phase
Stage II Prostate Adenocarcinoma Radiation: Intensity-Modulated Radiation Therapy (IMRT) Radiation: Stereotactic Body Radiation Therapy (SBRT) Phase 3

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related Quality of Life (HRQOL) as measured by Expanded Prostate Cancer Index Composite (EPIC)-26 at 24 months post completion of therapy.

SECONDARY OBJECTIVES:

I. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by disease free survival (DFS).

II. To determine whether SBRT can be shown to be superior to hypofractionated IMRT at 12 and 24 months post completion of therapy in terms of HRQOL by having fewer patients that experience a minimal important decline (MID) bowel (12 months only) sexual, hormonal, urinary irritation/obstructive (12 months only) and in urinary incontinence HRQOL as measured by EPIC-26.

III. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases.

IV. To determine if prostate imaging-reporting and data system (PIRADS)version (v)2 = 4/5 disease is predictive for biochemical failure.

TERTIARY OBJECTIVES:

I. To determine whether a potentially more expensive therapy, SBRT, would be cost-effective than standard hypofractionated IMRT as measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).

II. To determine if disease characteristics captured on MRI can be used to predict which patients will respond to SBRT versus hypofractionated IMRT.

III. Collect specimens for future translational research analyses.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients undergo IMRT once daily for 5 fractions per week for 28 fractions over less than 32 business days.

ARM II: Patients undergo SBRT at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.

After completion of study treatment, patients are followed up every 6-12 months until death or study termination.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 622 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Actual Study Start Date : November 16, 2017
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Active Comparator: Intensity-Modulated Radiation Therapy (IMRT)
Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • intensity-modulated radiation therapy
  • Intensity-Modulated Radiotherapy

Experimental: Stereotactic Body Radiation Therapy (SBRT)
Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Undergo SBRT
Other Names:
  • SABR
  • SBRT
  • Stereotactic Ablative Body Radiation Therapy
  • stereotactic body radiation therapy




Primary Outcome Measures :
  1. Incidence of Patients-Reported Gastrointestinal and Genitourinary Toxicity [ Time Frame: Up to 2 years ]
    Will be measured by Expanded Prostate Cancer Index Composite-(EPIC) 26 bowel and urinary irritation domains. Will be compared between treatment arms using a test of proportions with two-sided significance level of 0.05.

  2. Disease Free Survival [ Time Frame: Time to biochemical failure (Phoenix definition), local failure, regional failure, distant metastasis, or death from any cause, assessed up to 2 years ]
    Will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test.


Secondary Outcome Measures :
  1. Biochemical Failure [ Time Frame: yearsFrom the date of randomization to the date of biochemical failure, date of precluding death, or last known follow-up, assessed up to 5 years. ]
    Will be assessed by Phoenix definition.

  2. Distant Metastasis [ Time Frame: From the time of randomization to the date of distant metastasis, date of precluding death, or last known follow-up date , assessed for up to 5 years ]
    Will be assessed.

  3. Health Related Quality of Life [ Time Frame: Up to 2 years ]
    Will be measured by EPIC-26 urinary incontinence, sexual, and hormonal domains.

  4. Incidence of adverse events (AEs) [ Time Frame: Up to 2 years ]
    Will be assessed by Common Terminology Criteria for Adverse Events version 4. Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The number of patients with at least 1 grade 3 or higher AE will be compared between the treatment arms. A comparison between treatment arms of grade 3 and higher genitourinary (GU) and gastrointestinal (GI) events related to treatment (separately) will also be tested. There are 5 pre-specified AEs, dysuria, hematuria, incontinence, rectal bleeding,

  5. Local Failure [ Time Frame: From the time of randomization to the date of local failure, date of precluding death, or last known follow-up date, assessed for up to 5 years ]
    Will be assessed.

  6. Overall Survival [ Time Frame: From the date of randomization to the date of death or last known follow-up date, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test.

  7. Presence of Prostate Imaging-Reporting and Data System version (PIRADSv) 2 = 4/5 disease [ Time Frame: Baseline ]
    Will be assessed by magnetic resonance imaging (MRI).

  8. Prostate Cancer Specific Survival [ Time Frame: yearsFrom the date of randomization to the date of prostate cancer death, date of precluding death, or last known follow-up date, assessed up to 5 years ]
    Will be assessed.

  9. Regional Failure [ Time Frame: From the time of randomization to the date of local failure, date of precluding death, or last known follow-up date, assessed for up to 5 years ]
    Will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously untreated (no local therapy such as surgery, radiation cryotherapy, HIFU, etc.) localized adenocarcinoma of the prostate with the following clinical findings:

    • Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland); (American Joint Committee on Cancer [AJCC], version 7) or cT1a-c or 2a or 2b,
    • Stages T1a-T1b are eligible if patient underwent transurethral prostatic resection (TURP), the patient must meet one of the following 3 criteria: 1) Gleason score must be Gleason 7(3+4) with a PSA < 20 ng/mL, or 2) Gleason 6(3+3) with a PSA > 10 ng/mL and < 20 ng/mL; (AJCC, version 7) or 3) Group Grade 1 or 2

      • If patient is receiving a 5-alpha reductase inhibitor at the time of enrollment the baseline PSA value may be double the initial value and the medication should be discontinued but a washout period is not required to eligible, a PSA drawn while still on the medicine must be:

        • < 10 ng/mL if Gleason 7(3+4) (Note: This patient would be on stratification level 1 if PSA < 5 ng/mL and stratification level 2 if less than 10 ng/mL).
        • > 5 ng/mL and less than 10 ng/mL for Gleason 6(3+3) (Note: This patients would be on stratification level 3).
    • Percent of submitted positive core biopsies must be < 50% of all sextants (Sextant refers to the bilateral base, mid and apex of the gland and the left and right, resulting in six sections or sextants. Biopsies may take 2 from each sextant. If more than 12 are sampled, some may be from a targeted region possibly with multiple cores to ensure adequate tissue.)

      • NOTE: all cores from a targeted lesion will be counted as an N of 1 core for calculating percent positive cores in total
    • The prostate volume must be < 60 cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan
    • Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements
  • History and physical including a digital rectal exam 60 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 60 days prior to registration
  • MRI of pelvis (compliant with PIRADSv2 guidelines) within 90 days prior to registration
  • Bone scan or sodium fluoride positron emission tomography (PET) scan within 90 days prior to registration
  • Charlson modified co-morbidity score =< 3 for patients under 60 and =< 4 for patients 60 and over 21 days prior to registration
  • International prostate symptom score (IPSS) of < 15 21 days prior to registration
  • The patient must provide study-specific informed consent prior to study entry
  • Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire
  • Completion of all items of the EPIC-26 which will be data entered at registration 60 days prior to registration
  • Only English, Spanish, and French-speaking patients are eligible to participate

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis and a bone scan or sodium fluoride PET scan
  • Definitive T3 disease on MRI
  • Prior or current invasive malignancy with current evidence of active disease within the past 3 years
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment for at least 3 years; [applicable only to studies that incorporate systemic therapy]
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • The use of hormonal therapy is not allowed; if the patient in on a 5-alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate
  • Severe, active co-morbidity defined as follows:

    • Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
  • Contraindication to MRI

    • Cardiac pacemaker or defibrillator
    • Surgically implanted electrical devices such as spinal stimulation devices or intracranial stimulation devices, cochlear implants, the presence of metallic foreign bodies in the orbits, and incompatible old mechanical heart valves and aneurysm clips

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03367702


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Lewis and Faye Manderson Cancer Center Recruiting
Tuscaloosa, Alabama, United States, 35401
Contact: Site Public Contact    800-338-2948      
Principal Investigator: James C. Tucker         
United States, Arizona
Arizona Breast Cancer Specialists-Gilbert Recruiting
Gilbert, Arizona, United States, 85297
Contact: Site Public Contact    480-922-4600      
Principal Investigator: Terry T. Lee         
Arizona Center for Cancer Care-Peoria Recruiting
Peoria, Arizona, United States, 85381
Contact: Site Public Contact    623-773-2873      
Principal Investigator: Terry T. Lee         
Arizona Breast Cancer Specialists-Scottsdale Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Site Public Contact    480-922-4600      
Principal Investigator: Terry T. Lee         
Arizona Center for Cancer Care-Surprise Recruiting
Surprise, Arizona, United States, 85374
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Terry T. Lee         
Arizona Oncology Associates-West Orange Grove Recruiting
Tucson, Arizona, United States, 85704
Contact: Site Public Contact    520-544-2919      
Principal Investigator: Vivek S. Kavadi         
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Site Public Contact    501-686-8274      
Principal Investigator: Sanjay Maraboyina         
United States, California
Alta Bates Summit Medical Center-Herrick Campus Recruiting
Berkeley, California, United States, 94704
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Christopher U. Jones         
Fresno Cancer Center Recruiting
Fresno, California, United States, 93720
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Marin General Hospital Recruiting
Greenbrae, California, United States, 94904
Contact: Site Public Contact    415-925-7325      
Principal Investigator: Lloyd T. Miyawaki         
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Site Public Contact    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: Brent S. Rose         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Leslie Ballas         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Leslie Ballas         
Kaiser Permanente Oakland-Broadway Recruiting
Oakland, California, United States, 94611
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Stanford Cancer Institute Palo Alto Recruiting
Palo Alto, California, United States, 94304
Contact: Site Public Contact    650-498-7061    ccto-office@stanford.edu   
Principal Investigator: Hilary Bagshaw         
Kaiser Permanente-Rancho Cordova Cancer Center Recruiting
Rancho Cordova, California, United States, 95670
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Rohnert Park Cancer Center Recruiting
Rohnert Park, California, United States, 94928
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
The Permanente Medical Group-Roseville Radiation Oncology Recruiting
Roseville, California, United States, 95678
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: Richard K. Valicenti         
Stanford Cancer Center South Bay Suspended
San Jose, California, United States, 95124
Kaiser Permanente Medical Center - Santa Clara Recruiting
Santa Clara, California, United States, 95051
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Kaiser Permanente Cancer Treatment Center Recruiting
South San Francisco, California, United States, 94080
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Gene Upshaw Memorial Tahoe Forest Cancer Center Recruiting
Truckee, California, United States, 96161
Contact: Site Public Contact    530-582-6450      
Principal Investigator: Richard K. Valicenti         
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Site Public Contact    720-848-0650      
Principal Investigator: Thomas J. Pugh         
UCHealth Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Site Public Contact    719-365-2406      
Principal Investigator: Thomas J. Pugh         
Memorial Hospital North Recruiting
Colorado Springs, Colorado, United States, 80920
Contact: Site Public Contact    719-364-6700      
Principal Investigator: Thomas J. Pugh         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact    970-297-6150      
Principal Investigator: Thomas J. Pugh         
Valley View Hospital Cancer Center Recruiting
Glenwood Springs, Colorado, United States, 81601
Contact: Site Public Contact    970-384-7570      
Principal Investigator: Peter J. Rossi         
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Site Public Contact    203-785-5702    canceranswers@yale.edu   
Principal Investigator: James B. Yu         
United States, Delaware
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Christiana Care Health System-Christiana Hospital Recruiting
Newark, Delaware, United States, 19718
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Beebe Health Campus Recruiting
Rehoboth Beach, Delaware, United States, 19971
Contact: Site Public Contact    302-645-3100    Dmiskin@Beebehealthcare.org   
Principal Investigator: Gregory A. Masters         
United States, Georgia
Grady Health System Recruiting
Atlanta, Georgia, United States, 30303
Contact: Site Public Contact    404-489-9164      
Principal Investigator: Ashesh B. Jani         
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Site Public Contact    888-946-7447      
Principal Investigator: Ashesh B. Jani         
Piedmont Hospital Recruiting
Atlanta, Georgia, United States, 30309
Contact: Site Public Contact    404-425-7943    ORS@piedmont.org   
Principal Investigator: Adam W. Nowlan         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Site Public Contact    404-778-1868      
Principal Investigator: Ashesh B. Jani         
Emory Saint Joseph's Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Ashesh B. Jani         
Piedmont Fayette Hospital Recruiting
Fayetteville, Georgia, United States, 30214
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Adam W. Nowlan         
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Howard A. Zaren         
United States, Illinois
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Edward Hines Jr VA Hospital Recruiting
Hines, Illinois, United States, 60141
Contact: Site Public Contact    708-202-8387      
Principal Investigator: Abhishek A. Solanki         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Site Public Contact    708-226-4357      
Principal Investigator: Abhishek A. Solanki         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Daniel H. Barnett         
United States, Indiana
Parkview Hospital Randallia Active, not recruiting
Fort Wayne, Indiana, United States, 46805
Parkview Regional Medical Center Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Site Public Contact    877-784-4673      
Principal Investigator: Brian K. Chang         
Franciscan Health Indianapolis Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Site Public Contact    317-528-7060      
Principal Investigator: Valeri Goutsouliak         
United States, Kansas
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Xinglei Shen         
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Xinglei Shen         
Via Christi Regional Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
United States, Louisiana
East Jefferson General Hospital Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
LSU Healthcare Network / Metairie Multi-Specialty Clinic Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
United States, Maine
MaineHealth Coastal Cancer Treatment Center Recruiting
Bath, Maine, United States, 04530
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Matthew D. Cheney         
Maine Medical Center-Bramhall Campus Recruiting
Portland, Maine, United States, 04102
Contact: Site Public Contact    207-885-7565      
Principal Investigator: Matthew D. Cheney         
MaineHealth Cancer Care Center of York County Recruiting
Sanford, Maine, United States, 04073
Contact: Site Public Contact    207-459-1600      
Principal Investigator: Matthew D. Cheney         
Maine Medical Center- Scarborough Campus Recruiting
Scarborough, Maine, United States, 04074
Contact: Site Public Contact    207-396-8090    wrighd@mmc.org   
Principal Investigator: Matthew D. Cheney         
United States, Maryland
Saint Agnes Hospital Recruiting
Baltimore, Maryland, United States, 21229
Contact: Site Public Contact    410-368-2910      
Principal Investigator: Richard S. Hudes         
Peninsula Regional Medical Center Recruiting
Salisbury, Maryland, United States, 21801
Contact: Site Public Contact    866-922-6237      
Principal Investigator: John R. Mansueti         
United States, Massachusetts
Boston Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Site Public Contact    617-638-8265      
Principal Investigator: Ariel E. Hirsch         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Samir Narayan         
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Site Public Contact    800-865-1125      
Principal Investigator: Daniel E. Spratt         
McLaren Cancer Institute-Bay City Recruiting
Bay City, Michigan, United States, 48706
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
21st Century Oncology MHP - Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    248-338-0663      
Principal Investigator: Frank A. Vicini         
McLaren Cancer Institute-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
Beaumont Hospital ? Dearborn Recruiting
Dearborn, Michigan, United States, 48124
Contact: Site Public Contact    313-593-8090      
Principal Investigator: Zachary A. Seymour         
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
21st Century Oncology MHP - Farmington Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Site Public Contact    248-338-0663      
Principal Investigator: Frank A. Vicini         
Weisberg Cancer Treatment Center Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
McLaren Cancer Institute-Flint Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
McLaren-Greater Lansing Recruiting
Lansing, Michigan, United States, 48910
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
McLaren Cancer Institute-Macomb Recruiting
Mount Clemens, Michigan, United States, 48043
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
McLaren Cancer Institute-Northern Michigan Recruiting
Petoskey, Michigan, United States, 49770
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
McLaren-Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Neal H. Bhatt         
William Beaumont Hospital-Royal Oak Recruiting
Royal Oak, Michigan, United States, 48073
Contact: Site Public Contact    248-551-7695      
Principal Investigator: Zachary A. Seymour         
William Beaumont Hospital - Troy Recruiting
Troy, Michigan, United States, 48085
Contact: Site Public Contact    248-551-7695      
Principal Investigator: Zachary A. Seymour         
21st Century Oncology MHP - Troy Recruiting
Troy, Michigan, United States, 48098
Contact: Site Public Contact    248-338-0663      
Principal Investigator: Frank A. Vicini         
United States, Minnesota
Sanford Joe Lueken Cancer Center Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact    218-333-5000    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
United States, Missouri
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
Southeast Cancer Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-651-5550      
Principal Investigator: Bryan A. Faller         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Jeff M. Michalski         
Siteman Cancer Center-South County Recruiting
Saint Louis, Missouri, United States, 63129
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Jeff M. Michalski         
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Siteman Cancer Center at Saint Peters Hospital Recruiting
Saint Peters, Missouri, United States, 63376
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Jeff M. Michalski         
United States, Montana
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Site Public Contact    402-559-6941    unmcrsa@unmc.edu   
Principal Investigator: Charles A. Enke         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Site Public Contact    800-639-6918    cancer.research.nurse@dartmouth.edu   
Principal Investigator: Nirav S. Kapadia         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Site Public Contact    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Thomas M. Schroeder         
Lovelace Radiation Oncology Recruiting
Albuquerque, New Mexico, United States, 87109
Contact: Site Public Contact    505-272-0530    AYost@nmcca.org   
Principal Investigator: Thomas M. Schroeder         
New Mexico Oncology Hematology Consultants Recruiting
Albuquerque, New Mexico, United States, 87109
Contact: Site Public Contact    505-272-0530    CLee@nmcca.org   
Principal Investigator: Thomas M. Schroeder         
United States, New York
New York-Presbyterian/Brooklyn Methodist Hospital Recruiting
Brooklyn, New York, United States, 11215
Contact: Site Public Contact    718-780-3677    Adg9003@nyp.org   
Principal Investigator: Hani L. Ashamalla         
Mary Imogene Bassett Hospital Recruiting
Cooperstown, New York, United States, 13326
Contact: Site Public Contact    877-547-1750    CancerClinicalTrials@bassett.org   
Principal Investigator: Timothy P. Korytko         
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Site Public Contact    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Peter B. Schiff         
Highland Hospital Recruiting
Rochester, New York, United States, 14620
Contact: Site Public Contact    585-341-8113      
Principal Investigator: Yuhchyau Chen         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Site Public Contact    585-275-5830      
Principal Investigator: Yuhchyau Chen         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact    888-275-3853      
Principal Investigator: Bridget F. Koontz         
NHRMC Radiation Oncology - Supply Recruiting
Supply, North Carolina, United States, 28462
Contact: Site Public Contact    910-754-4716      
Principal Investigator: Michael A. Papagikos         
NHRMC Radiation Oncology - 16th Street Recruiting
Wilmington, North Carolina, United States, 28401
Contact: Site Public Contact    910-251-1839      
Principal Investigator: Michael A. Papagikos         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-234-6161    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
United States, Ohio
Cleveland Clinic Akron General Recruiting
Akron, Ohio, United States, 44307
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mitchel L. Fromm         
UHHS-Chagrin Highlands Medical Center Suspended
Beachwood, Ohio, United States, 44122
Geauga Hospital Suspended
Chardon, Ohio, United States, 44024
Case Western Reserve University Suspended
Cleveland, Ohio, United States, 44106
Cleveland Clinic Cancer Center/Fairview Hospital Recruiting
Cleveland, Ohio, United States, 44111
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Lanea Keller         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Dayssy A. Diaz Pardo         
Mercy Cancer Center-Elyria Suspended
Elyria, Ohio, United States, 44035
Cleveland Clinic Cancer Center Independence Active, not recruiting
Independence, Ohio, United States, 44131
Cleveland Clinic Cancer Center Mansfield Recruiting
Mansfield, Ohio, United States, 44906
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Lanea Keller         
Hillcrest Hospital Cancer Center Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Lanea Keller         
UH Seidman Cancer Center at Lake Health Mentor Campus Suspended
Mentor, Ohio, United States, 44060
North Coast Cancer Care Recruiting
Sandusky, Ohio, United States, 44870
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Lanea Keller         
UHHS-Westlake Medical Center Suspended
Westlake, Ohio, United States, 44145
Cleveland Clinic Wooster Family Health and Surgery Center Recruiting
Wooster, Ohio, United States, 44691
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Lanea Keller         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: J. S. Thompson         
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Samir Narayan         
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Christiana Care Health System-Concord Health Center Recruiting
Chadds Ford, Pennsylvania, United States, 19317
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Delaware County Memorial Hospital Recruiting
Drexel Hill, Pennsylvania, United States, 19026
Contact: Site Public Contact    610-284-8237    jolene.garney@crozer.org   
Principal Investigator: Rachelle M. Lanciano         
Geisinger Medical Oncology-Lewisburg Recruiting
Lewisburg, Pennsylvania, United States, 17837
Contact: Site Public Contact    570-374-8555    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Site Public Contact    215-955-6084      
Principal Investigator: Robert B. Den         
Aria Health-Torresdale Campus Recruiting
Philadelphia, Pennsylvania, United States, 19114
Contact: Site Public Contact    215-612-5296      
Principal Investigator: Robert B. Den         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
Geisinger Wyoming Valley/Henry Cancer Center Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Abington Memorial Hospital-Asplundh Cancer Pavilion Recruiting
Willow Grove, Pennsylvania, United States, 19090
Contact: Site Public Contact    215-481-2402      
Principal Investigator: Wayne H. Pinover         
Lankenau Medical Center Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
WellSpan Health-York Cancer Center Recruiting
York, Pennsylvania, United States, 17403
Contact: Site Public Contact    877-441-7957      
Principal Investigator: Amit B. Shah         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Site Public Contact    843-792-9321    hcc-clinical-trials@musc.edu   
Principal Investigator: David T. Marshall         
Greenville Health System Cancer Institute-Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Michael D. Zurenko         
Greenville Health System Cancer Institute-Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Michael D. Zurenko         
Self Regional Healthcare Recruiting
Greenwood, South Carolina, United States, 29646
Contact: Site Public Contact    864-725-4771    nmcgaha@selfregional.org   
Principal Investigator: David T. Marshall         
Greenville Health System Cancer Institute-Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Michael D. Zurenko         
The Radiation Oncology Center-Hilton Head/Bluffton Recruiting
Hilton Head Island, South Carolina, United States, 29926
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
Greenville Health System Cancer Institute-Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Michael D. Zurenko         
Greenville Health System Cancer Institute-Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Michael D. Zurenko         
United States, South Dakota
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Preston D. Steen         
United States, Tennessee
Thompson Cancer Survival Center Recruiting
Knoxville, Tennessee, United States, 37916
Contact: Site Public Contact    865-331-1812      
Principal Investigator: Grant M. Clark         
United States, Texas
Texas Cancer Center Recruiting
Abilene, Texas, United States, 79606
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-McKinney Recruiting
McKinney, Texas, United States, 75071
Contact: Site Public Contact    972-542-8609      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-Plano West Recruiting
Plano, Texas, United States, 75093
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Vivek S. Kavadi         
Texas Oncology Cancer Center Sugar Land Recruiting
Sugar Land, Texas, United States, 77479
Contact: Site Public Contact    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Deke Slayton Cancer Center Recruiting
Webster, Texas, United States, 77598
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Vivek S. Kavadi         
United States, Utah
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84107
Contact: Site Public Contact    801-507-3950    officeofresearch@imail.org   
Principal Investigator: R. J. Lee         
Utah Valley Regional Medical Center Recruiting
Provo, Utah, United States, 84604
Contact: Site Public Contact    801-357-7965    officeofresearch@imail.org   
Principal Investigator: R. J. Lee         
United States, Vermont
Central Vermont Medical Center/National Life Cancer Treatment Recruiting
Berlin, Vermont, United States, 05602
Contact: Site Public Contact    802-225-5400      
Principal Investigator: Nataniel H. Lester-Coll         
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Site Public Contact    802-656-4101    rpo@uvm.edu   
Principal Investigator: Nataniel H. Lester-Coll         
Norris Cotton Cancer Center-North Recruiting
Saint Johnsbury, Vermont, United States, 05819
Contact: Site Public Contact    802-473-4100      
Principal Investigator: Nirav S. Kapadia         
United States, Virginia
Bon Secours DePaul Medical Center Recruiting
Norfolk, Virginia, United States, 23505
Contact: Site Public Contact    804-893-8611    Melissa_Godsey@bshsi.org   
Principal Investigator: William J. Irvin         
Sentara Norfolk General Hospital Recruiting
Norfolk, Virginia, United States, 23507
Contact: Site Public Contact    757-388-2406      
Principal Investigator: Mark E. Shaves         
Oncology and Hematology Associates of Southwest Virginia Recruiting
Roanoke, Virginia, United States, 24014
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Vivek S. Kavadi         
United States, West Virginia
West Virginia University Charleston Division Recruiting
Charleston, West Virginia, United States, 25304
Contact: Site Public Contact    304-388-9944      
Principal Investigator: Steven J. Jubelirer         
West Virginia University Healthcare Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Site Public Contact    304-293-7374    cancertrialsinfo@hsc.wvu.edu   
Principal Investigator: Malcolm D. Mattes         
United States, Wisconsin
Ascension Saint Elizabeth Hospital Recruiting
Appleton, Wisconsin, United States, 54915
Contact: Site Public Contact    920-831-8900    Dale.grimmer@ascension.org   
Principal Investigator: Robert R. Kohl         
Wheaton Franciscan Healthcare-Elmbrook Memorial Hospital Recruiting
Brookfield, Wisconsin, United States, 53045
Contact: Site Public Contact    262-687-5010    Michelle.czechowicz@ascension.org   
Principal Investigator: Lewis A. Rosenberg         
Wheaton Franciscan Healthcare-Saint Francis/Reiman Cancer Center Recruiting
Franklin, Wisconsin, United States, 53132
Contact: Site Public Contact    262-687-5010    Michelle.czechowicz@ascension.org   
Principal Investigator: Lewis A. Rosenberg         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Collin D. Driscoll         
Community Memorial Hospital Recruiting
Menomonee Falls, Wisconsin, United States, 53051
Contact: Site Public Contact    262-257-5100      
Principal Investigator: Colleen A. Lawton         
Columbia Saint Mary's Hospital - Ozaukee Recruiting
Mequon, Wisconsin, United States, 53097
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Craig A. Schulz         
Columbia Saint Mary's Water Tower Medical Commons Recruiting
Milwaukee, Wisconsin, United States, 53211
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Craig A. Schulz         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Ellen L. Ziaja         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Site Public Contact    414-805-4380      
Principal Investigator: Colleen A. Lawton         
Ascension Mercy Hospital Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    920-831-8900    Dale.grimmer@ascension.org   
Principal Investigator: Robert R. Kohl         
Wheaton Franciscan Cancer Care - All Saints Recruiting
Racine, Wisconsin, United States, 53405
Contact: Site Public Contact    262-687-5010    Michelle.czechowicz@ascension.org   
Principal Investigator: Lewis A. Rosenberg         
The Alyce and Elmore Kraemer Cancer Care Center Recruiting
West Bend, Wisconsin, United States, 53095
Contact: Site Public Contact    866-680-0505      
Principal Investigator: Colleen A. Lawton         
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Site Public Contact    403-521-3433      
Principal Investigator: Harvey C. Quon         
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact    780-432-8500      
Principal Investigator: Brita L. Danielson         
Canada, Ontario
Ottawa Hospital and Cancer Center-General Campus Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site Public Contact    613-761-4395      
Principal Investigator: Scott C. Morgan         
Canada, Quebec
Centre De Sante Et De Services Sociaux De Chicoutimi Recruiting
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Marc-Andre Brassard         
CIUSSSEMTL-Hopital Maisonneuve-Rosemont Recruiting
Montreal, Quebec, Canada, H1T 2M4
Contact: Site Public Contact    514-252-3400 ext 3329      
Principal Investigator: Peter Vavassis         
CHUM - Centre Hospitalier de l'Universite de Montreal Recruiting
Montreal, Quebec, Canada, H2X 3E4
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Carole Lambert         
The Research Institute of the McGill University Health Centre (MUHC) Suspended
Montreal, Quebec, Canada, H3H 2R9
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Recruiting
Quebec City, Quebec, Canada, G1R 2J6
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Andre-Guy Martin         
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Site Public Contact    819-820-6480    crcinformation.chus@ssss.gouv.qc.ca   
Principal Investigator: Audrey Tetreault-Laflamme         
Canada, Saskatchewan
Allan Blair Cancer Centre Recruiting
Regina, Saskatchewan, Canada, S4T 7T1
Contact: Site Public Contact    306-766-2213      
Principal Investigator: Evgeny Sadikov         
Saskatoon Cancer Centre Recruiting
Saskatoon, Saskatchewan, Canada, S7N 4H4
Contact: Site Public Contact    306-655-2914      
Principal Investigator: Ali A. El-Gayed         
Ireland
Beacon Hospital Recruiting
Dublin, Co Dublin, Ireland, 18
Contact: Site Public Contact    353 1 2936691      
Principal Investigator: Alina M. Mihai         
Sponsors and Collaborators
NRG Oncology
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Rodney Ellis NRG Oncology

Layout table for additonal information
Responsible Party: NRG Oncology
ClinicalTrials.gov Identifier: NCT03367702     History of Changes
Other Study ID Numbers: NRG-GU005
NCI-2017-01398 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-GU005 ( Other Identifier: NRG Oncology )
NRG-GU005 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: December 11, 2017    Key Record Dates
Last Update Posted: June 20, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Adenocarcinoma
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type